Management of disseminated disease in the patient with bladder cancer.
Advanced transitional cell carcinoma of the bladder is a chemotherapy-sensitive neoplasm. Several single agents demonstrate substantial activity, and combination chemotherapy produces responses in the majority of patients treated. The benefits and toxicities associated with the most widely used combination regimens are discussed. Other topics reviewed include the use of colony-stimulating factor support for chemotherapy, adjunctive surgical therapy, and newer cytotoxic regimens.